Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Gaining Momentum in the Treatment of Eye Disease

Avalanche develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat ophthalmologic disorders.

Our lead product treats age-related macular degeneration (AMD) by using the body's own cells to produce therapeutic proteins on an ongoing basis after only a single injection. The goal is effective long-term treatment of wet AMD without the burden of frequent, ongoing intra-ocular injections.

Read More

Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing

April 22, 2014

– Proceeds will Further Strengthen Avalanche’s Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration –


MENLO PARK, Calif., April 22, 2014 -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and included Deerfield, Adage Capital Management, Redmile Group, Rock Springs Capital, Sabby Capital, as well as an affiliate of Cowen & Company and two undisclosed blue chip health care funds; joining the existing investors. Cowen & Company acted as sole placement agent for the financing.

Read More

Read All Avalanche News